Step 8 of 10 · Decision support
Treatment plan
What this step shows
The recommended next treatment step, following statin → ezetimibe → PCSK9 inhibitor and taking intolerance and time on therapy into account.
Clinical pathway
Primary Prevention — Diabetes pathway
Risk category
High
LDL-C target
<1.8 mmol/L
Recommended next step
Consider PCSK9 inhibitor pathway (e.g. evolocumab / alirocumab)
Maximally tolerated statin + ezetimibe therapy (or documented intolerance) for ≥3 months, still above target — clinically appropriate to consider a PCSK9 inhibitor. This triggers the Swiss Reimbursement Engine.
→ Swiss reimbursement check follows in the next step
Current therapy on record
High-intensity statin (Atorvastatin 80 mg) + ezetimibe · 5 month(s) on this regimen
Edit
How this was decided
- ✕ LDL-C already at target? 2.1 mmol/L vs. target <1.8 mmol/L.
- ✓ Currently on a statin? High-intensity statin.
- ✓ On ezetimibe? Ezetimibe already added.
- ✓ At least 3 months on the current combination? 5 month(s) on the current regimen.